⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 1, 2024Open Access

Figure S11 from CD46-Targeted Theranostics for PET and ²²⁵Ac-Radiopharmaceutical Therapy of Multiple Myeloma

Anju Wadhwa Sinan Wang Bonell Patiño-Escobar Anil P. Bidkar Kondapa Naidu Bobba Emily Chan Niranjan Meher Scott Bidlingmaier Yang Su Suchi Dhrona Huimin Geng Vishesh Sarin Henry F. VanBrocklin David M. Wilson Jiang He Li Zhang Veronica Steri Sandy W. Wong Thomas G. Martin Youngho Seo Bin Liu Arun P. Wiita Robert R. Flavell

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S11: %ID/Tumor of [89Zr]Zr-DFO-YS5 in ANBL6 subcutaneous model is higher than RPMI8226 and MM.1S.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wadhwa et al. (2024) studied this question.

synapsesocial.com/papers/68e7681cb6db6435876dd057 https://doi.org/10.1158/1078-0432.25324409

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S10 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma2024
2Table S10 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma2024
3Table S9 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma2024
4Table S9 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma2024
5Figure S3 from CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma2024